Bictegravir/lenacapavir (Bixlenvo) vs Lenacapavir (Yeztugo)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV capsid · full HIV pipeline

Bictegravir/lenacapavir (Bixlenvo)

Marketed by Gilead Sciences

Approved in HIVsmall molecule
Partial signal

NCT05502341 · Phase 2/3 · active, not recruiting

This was a randomized, active-controlled trial in 557 people in its Phase 3 part, but it was open-label, so participants and investigators knew which treatment each person received. Its primary endpoint, the proportion with detectable HIV-1 RNA at week 48, is an objective laboratory measure, and bictegravir/lenacapavir met the non-inferiority goal against continued complex regimens.

Next expected readout: July 2028 · NCT07908446 (registry estimate)

Reported efficacy

Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm; Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm: Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). (met)

Result source: NCT05502341

Lenacapavir (Yeztugo)

Marketed by Gilead Sciences

Approved in HIVsmall molecule
Reliable signal

NCT04994509 · Phase 3 · active, not recruiting

This is a very large randomized, double-blind trial with active-control arms and a hard primary endpoint, HIV-1 infection. Lenacapavir's HIV incidence was far below the background rate and met the prespecified superiority tests. The primary comparison is against a background rate estimated from screened participants, not directly against the control arms.

Next expected readout: March 2027 · NCT07210125 (registry estimate)

Reported efficacy

Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY) (Incidence Phase Screening Visit (Day 1)); Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set) (Up to 149 weeks): HIV incidence: 0.10 per 100 PY on twice-yearly lenacapavir (2 infections) vs background incidence 2.37 per 100 PY (IRR 0.04; 95% CI 0.01-0.18; P<0.001) and vs F/TDF 0.93 per 100 PY (IRR 0.11; 95% CI 0.02-0.51; P=0.002) (PURPOSE 2, NEJM 2025). (met)

Result source: NCT04925752

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBictegravir/​lenacapavir (Bixlenvo)Lenacapavir (Yeztugo)
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT06532656—Trial running · NCT04925752
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT06532656—Trial running · NCT04925752
CD4 count, change (week 48)—Trial running · NCT06532656—Trial running · NCT04925752

HIV-1 RNA below 50 copies/mL (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
Lenacapavir (Yeztugo)
—Trial running · NCT04925752

HIV-1 RNA 50 copies/mL or more (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
Lenacapavir (Yeztugo)
—Trial running · NCT04925752

CD4 count, change (week 48)

Bictegravir/​lenacapavir (Bixlenvo)
—Trial running · NCT06532656
Lenacapavir (Yeztugo)
—Trial running · NCT04925752
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Bictegravir/lenacapavir (Bixlenvo)
Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). NCT05502341 · Phase 2/3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Bictegravir/lenacapavir (Bixlenvo): 0 of 4 rows · Lenacapavir (Yeztugo): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLenacapavir (Yeztugo)
Dropout rate
11.5%
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
94.4%
NCT04925752 · Phase 3 · combination · HIV · phase 3
Discontinued due to AEs
0.1%
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
0.2%
NCT04925752 · Phase 3 · combination · HIV · phase 3
Serious AEs
3.8%
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
3.3%
NCT04925752 · Phase 3 · combination · HIV · phase 3
Most frequent reported AEs
injection site nodule 66.1%
injection site pain 34.2%
genitourinary chlamydia infection 16.4%
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
injection site nodule 63.4%
injection site pain 56.4%
injection site erythema 17.3%
NCT04925752 · Phase 3 · combination · HIV · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lenacapavir (Yeztugo)

HIV-1 Incidence Per 100 PY 0 vs 2.018 F/TAF per 100 person year @ 52wk
event count · per 100 person year
NCT04994509 · Phase 3 · combination · HIV · phase 3
show 1 more result
0 vs 2.018 F/TAF per 100 person year @ 52wk
NCT04994509 · Phase 3 · combination · HIV · phase 3
HIV-1 Incidence Per 100 PY 0 per 100 person year @ 52wk
event count · per 100 person year
No placebo or comparator arm
NCT04994509 · Phase 3 · combination · HIV · phase 3
HIV-1 Incidence Rate Per 100 PY 0.103 per 100 person year @ 149wk
event rate · per 100 person year
No placebo or comparator arm
NCT04925752 · Phase 3 · combination · HIV · phase 3
show 1 more result
0.125 per 100 person year @ 149wk
NCT04925752 · Phase 3 · combination · HIV · phase 3
HIV-1 Incidence Rate Per 100 PY 0.103 vs 0.931 F/TDF per 100 person year @ 149wk
event rate · per 100 person year
NCT04925752 · Phase 3 · combination · HIV · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bictegravir/lenacapavir (Bixlenvo)'s landscape · Lenacapavir (Yeztugo)'s landscape